Phenotypes associated with this allele

• Allele Symbol: Tg(Lck*F505)3073Rmp
• Allele Name: transgene insertion 3073, Roger M Perlmutter
• Allele ID: MGI:3032775
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Ptprc^tm1Holm/Ptprc^tm1Holm Tg(Lck*F505)3073Rmp/?	involves: 129/Sv * C57BL/6 * DBA/2	MGI:3032910
cx2	Lat^tm4.1Mal/Lat^tm4.1Mal Tg(Lck*F505)3073Rmp/?	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:4357976
tg3	Tg(Lck*F505)3073Rmp/?	involves: C57BL/6J * DBA/2	MGI:3032815

Genotype
MGI:3032910

cx1

• Allelic Composition: Ptprc^tm1Holm/Ptprc^tm1Holm; Tg(Lck*F505)3073Rmp/?
• Genetic Background: involves: 129/Sv * C57BL/6 * DBA/2

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased T cell derived lymphoma incidence ( J:64671 )

• aggressive thymic tumors in 100% of mice

• earliest morbidity at 10 weeks and median survival was to 12 weeks

immune system

thymus hyperplasia ( J:64671 )

• thymus glands with tumours also have 5X normal cell numbers

increased T cell derived lymphoma incidence ( J:64671 )

• aggressive thymic tumors in 100% of mice

• earliest morbidity at 10 weeks and median survival was to 12 weeks

hematopoietic system

thymus hyperplasia ( J:64671 )

• thymus glands with tumours also have 5X normal cell numbers

increased T cell derived lymphoma incidence ( J:64671 )

• aggressive thymic tumors in 100% of mice

• earliest morbidity at 10 weeks and median survival was to 12 weeks

endocrine/exocrine glands

thymus hyperplasia ( J:64671 )

• thymus glands with tumours also have 5X normal cell numbers

increased T cell derived lymphoma incidence ( J:64671 )

• aggressive thymic tumors in 100% of mice

• earliest morbidity at 10 weeks and median survival was to 12 weeks

Genotype
MGI:4357976

cx2

• Allelic Composition: Lat^tm4.1Mal/Lat^tm4.1Mal; Tg(Lck*F505)3073Rmp/?
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2

immune system

spleen hyperplasia ( J:151840 )

• spleen cellularity is increased 3-fold compared to transgenics on a wild-type background

increased CD4-positive, alpha-beta T cell number ( J:151840 )

• CD4⁺CD5⁺ T cell numbers are increased over 5-fold compared to controls

increased IgE level ( J:151840 )

• serum IgE levels are about 10,000-fold higher than controls

increased IgG1 level ( J:151840 )

• serum IgG1 levels are more than 100-fold higher than controls

abnormal T-helper 2 physiology ( J:151840 )

• transgene allows rescue of deficient thymocyte development of Lat-null mice

• 60% of these T cells express IL-4 upon PMA stimulation

• Th2 T cells hyper proliferate and stimulate immunoglobulin production

increased interleukin-4 secretion ( J:151840 )

• 60% of peripheral T cells express IL-4 upon PMA stimulation

hematopoietic system

spleen hyperplasia ( J:151840 )

• spleen cellularity is increased 3-fold compared to transgenics on a wild-type background

increased CD4-positive, alpha-beta T cell number ( J:151840 )

• CD4⁺CD5⁺ T cell numbers are increased over 5-fold compared to controls

increased IgE level ( J:151840 )

• serum IgE levels are about 10,000-fold higher than controls

increased IgG1 level ( J:151840 )

• serum IgG1 levels are more than 100-fold higher than controls

abnormal T-helper 2 physiology ( J:151840 )

• transgene allows rescue of deficient thymocyte development of Lat-null mice

• 60% of these T cells express IL-4 upon PMA stimulation

• Th2 T cells hyper proliferate and stimulate immunoglobulin production

growth/size/body

spleen hyperplasia ( J:151840 )

• spleen cellularity is increased 3-fold compared to transgenics on a wild-type background

Genotype
MGI:3032815

tg3

• Allelic Composition: Tg(Lck*F505)3073Rmp/?
• Genetic Background: involves: C57BL/6J * DBA/2

neoplasm

neoplasm ( J:88309 )

N • unlike mice carrying transgenes of this gene which express greater than 20 pg of mRNA per ug of total RNA, no thymic tumors develop during the first year of life